Halozyme Therapeutics (NASDAQ:HALO) Issues Quarterly Earnings Results

Halozyme Therapeutics (NASDAQ:HALO) issued its earnings results on Monday. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06, FiscalAI reports. The company had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The firm’s quarterly revenue was up 42.2% on a year-over-year basis. During the same period in the prior year, the business earned $1.11 EPS. Halozyme Therapeutics updated its FY 2026 guidance to 7.750-8.250 EPS.

Here are the key takeaways from Halozyme Therapeutics’ conference call:

• Halozyme reported strong Q1 results with royalty revenue up 43% to $241M, total revenue of $377M (+42%), adjusted EBITDA of $230M and non-GAAP EPS of $1.60, and the company reaffirmed its full-year 2026 and 2026–2028 guidance (ENHANZE royalties projected to exceed $1 billion in 2026 and adjusted EBITDA margins >65%).
• Management highlighted four 2029+ revenue drivers: continued contribution from the 10 launched ENHANZE products (they estimate ~66% of projected royalties remain to be realized 2026–2032), up to 13 ENHANZE launches starting in 2029, two Hypercon launches targeted 2030–2031 with phase I starts planned in H1 2027, and further launches from additional nominations and new agreements.
• Board authorized a new $1 billion share repurchase program with an expectation to buy at least $400M in 2026 (targeting ~3% annual buyback yield); capital priorities also include reinvesting in ENHANZE/Hypercon/SurfBio and retiring 2027–2028 notes to further deleverage.
• Halozyme signed three 2026 collaboration/licensing agreements (including with GSK for ENHANZE ADCs, Vertex for Hypercon targets, and Oruka for Hypercon/ORKA?001), noting upfronts, potential milestones and mid?single?digit royalties as validation of demand for ENHANZE and Hypercon.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $66.41 on Tuesday. The stock has a market cap of $7.87 billion, a PE ratio of 26.67, a P/E/G ratio of 0.26 and a beta of 0.89. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. Halozyme Therapeutics has a twelve month low of $47.50 and a twelve month high of $82.22. The stock has a fifty day simple moving average of $65.68 and a 200-day simple moving average of $68.57.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Halozyme reported Q1 EPS of $1.60, above estimates, and revenue of $376.7 million, also ahead of forecasts, driven by 42% year-over-year sales growth. Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
• Positive Sentiment: The company announced a new $1 billion share repurchase program and said it expects to buy back at least $400 million in 2026, signaling confidence in cash generation and future earnings power. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
• Neutral Sentiment: Halozyme reiterated full-year 2026 guidance of $1.71 billion to $1.81 billion in revenue and non-GAAP EPS of $7.75 to $8.25, which was broadly in line with recent expectations but not a major upside surprise. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
• Negative Sentiment: Although Q1 was solid, the company’s EPS guidance range came in slightly below the consensus estimate, which may temper some of the post-earnings enthusiasm. Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say

Analysts Set New Price Targets

Several analysts have issued reports on the company. Weiss Ratings cut Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Tuesday, February 24th. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. HC Wainwright upped their target price on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Wells Fargo & Company upped their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a report on Thursday, February 19th. Finally, Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 21st. Six analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $79.11.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total transaction of $1,284,800.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $49,322,187.20. This represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 20,000 shares of the stock in a transaction on Monday, March 9th. The stock was sold at an average price of $67.80, for a total value of $1,356,000.00. Following the transaction, the chief operating officer owned 14,366 shares of the company’s stock, valued at approximately $974,014.80. This represents a 58.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 90,482 shares of company stock worth $6,073,942. 2.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds have recently modified their holdings of HALO. Larson Financial Group LLC lifted its stake in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares in the last quarter. Wexford Capital LP acquired a new position in Halozyme Therapeutics during the 3rd quarter worth about $70,000. Employees Retirement System of Texas lifted its stake in Halozyme Therapeutics by 64.6% during the 3rd quarter. Employees Retirement System of Texas now owns 1,088 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 427 shares in the last quarter. UMB Bank n.a. lifted its stake in Halozyme Therapeutics by 18.2% during the 4th quarter. UMB Bank n.a. now owns 1,296 shares of the biopharmaceutical company’s stock worth $87,000 after acquiring an additional 200 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in Halozyme Therapeutics by 21.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the biopharmaceutical company’s stock worth $95,000 after acquiring an additional 251 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.